1 CETP and SGLT2 inhibitor combination therapy improves

2 glycemic control

- 3 Bohdan B. Khomtchouk, PhD^{1,2,3,4,*}; Patrick Sun, BS¹; Marc Ditmarsch, MD⁵; John J.P.
- 4 Kastelein⁶, MD, PhD; Michael H. Davidson, MD⁷
- 5
- ¹ Department of BioHealth Informatics, Luddy School of Informatics, Computing, and
 Engineering, Indiana University, Indianapolis, IN, USA.
- 8 ² Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine,
- 9 Indianapolis, IN, USA.
- ³ Krannert Cardiovascular Research Center, Indiana University School of Medicine,
 Indianapolis, IN, USA.
- ⁴ Center for Computational Biology & Bioinformatics, Indiana University School of Medicine,
 Indianapolis, IN, USA.
- ⁵ NewAmsterdam Pharma B.V., Naarden, 1411 DC, The Netherlands.
- ⁶ Department of Vascular Medicine, Academic Medical Center, University of Amsterdam,
- 16 Amsterdam, The Netherlands.
- ⁷ Department of Medicine, Section of Cardiology, University of Chicago, Chicago, IL, USA.
- 18
- 19
- 20 Word count: 2705
- 21
- 22 *Correspondence to: Bohdan Khomtchouk, PhD, 535 W. Michigan Street, Informatics &
- 23 Communications Technology Complex (IT) 477, Indianapolis, IN 46202 USA. Email:

^{24 &}lt;u>bokhomt@iu.edu</u> NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 Key Points

2	Question: Does combined genetic CETP and SGLT2 inhibition confer decreased glycated
3	hemoglobin or diabetes incidence compared to SGLT2 inhibition alone?
4	
5	Findings: In this cohort study, a 2x2 factorial Mendelian randomization analysis on the UK
6	Biobank reveals that combined genetic CETP and SGLT2 inhibition is associated with
7	decreased glycated hemoglobin and diabetes risk compared to both control and SGLT2
8	inhibition alone.
9	
10	Meaning: Our findings suggest that CETP inhibitors, which are currently in clinical trials to
11	treat cardiovascular disease, can be repurposed to treat metabolic disease in a combination
12	therapy approach with SGLT2 inhibitors.
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	

1 Abstract

2	Importance: Cholesteryl ester transfer protein (CETP) inhibition has been associated with
3	decreased risk of new-onset diabetes in past clinical trials exploring their efficacy in
4	cardiovascular disease and can potentially be repurposed to treat metabolic disease. Notably,
5	as an oral drug it can potentially be used to supplement existing oral drugs such as sodium-
6	glucose cotransporter 2 (SGLT2) inhibitors before patients are required to take injectable drugs
7	such as insulin.
8	
9	Objective: To identify whether CETP inhibitors could be used as an oral add-on to SGLT2
10	inhibition to improve glycemic control.
11	
12	Design, Setting, and Participants: 2x2 factorial Mendelian Randomization (MR) is
13	performed on the general population of UK Biobank participants with European ancestry.
14	
15	Exposures: Previously constructed genetic scores for CETP and SGLT2 function are
16	combined in a 2x2 factorial framework to characterize the associations between joint CETP
17	and SGLT2 inhibition compared to either alone.
18	
19	Main Outcomes and Measures: Glycated hemoglobin and type-2 diabetes incidence.
20	
21	Results: Data on 233,765 UK Biobank participants suggests that individuals with genetic
22	inhibition of both CETP and SGLT2 have significantly lower glycated hemoglobin levels
23	(mmol/mol) than control (Effect size: -0.136; 95% CI: -0.190 to -0.081; p-value: 1.09E-06),
24	SGLT2 inhibition alone (Effect size: -0.082; 95% CI: -0.140 to -0.024; p-value: 0.00558), and
25	CETP (1)

Furthermore, joint CETP and SGLT2 inhibition is associated with decreased incidence of
diabetes (log-odds ratio) compared to control (Effect size: -0.068; 95% CI: -0.115 to -0.021; pvalue: 4.44E-03) and SGLT2 inhibition alone (Effect size: -0.062; 95% CI: -0.112 to -0.012;
p-value: 0.0149).

5

6 Conclusions and Relevance: Our results suggest that CETP and SGLT2 inhibitor therapy may
7 improve glycemic control over SGLT2 inhibitors alone. Future clinical trials can explore
8 whether CETP inhibitors can be repurposed to treat metabolic disease and provide an oral
9 therapeutic option to benefit high-risk patients before escalation to injectable drugs such as
10 insulin or glucagon-like peptide 1 (GLP1) receptor agonists.

1 Introduction

2 Metabolic disease has some of the highest medical burden in the world, with nearly 35% of people (over 100 million patients) afflicted with some form of metabolic syndrome in the 3 United States alone, costing our healthcare system >\$250 billion annually¹. Despite the 4 5 extensive amount of research performed on developing treatments for metabolic disease, there 6 is an unmet need for understanding synergies between existing treatment when used in 7 combination therapies, which has been a major driving force behind improved outcomes in 8 other disease areas such as oncology. Furthermore, the growing understanding of an 9 intersection between cardiovascular and metabolic disease represents a rich knowledge base 10 from which combination therapies using treatments from these two intersecting disease 11 verticals can be used to develop innovative and effective therapies to achieve better outcomes. Here, we investigate whether combining the hyperlipidemia drug class of cholesteryl ester 12 13 transfer protein (CETP) inhibitors with the existing hyperglycemia treatment in sodium glucose 14 transporter 2 (SGLT2) inhibitors is an effective strategy to improve glycemic control. SGLT2 inhibitors are a novel class of oral antidiabetic drugs that reduce glucose toxicity by stimulating 15 its excretion into urine and inhibiting its reabsorption in the kidneys^{2,3}. Because this 16 17 mechanism of action is independent of insulin secretion or action, SGLT2i can be used in combination with other therapies to improve outcomes for patients afflicted with type II 18 19 diabetes mellitus (T2DM)⁴. Circulating levels of plasma CETP reduce pancreatic β -cell insulin 20 secretion by disrupting cholesterol homeostasis through accumulation of free cholesterol, 21 which causes β -cell lipotoxicity and dysfunction that induces T2DM⁵. Therefore, CETP 22 inhibition is one promising approach to ameliorating β -cell function in T2DM by decreasing islet cholesterol accumulation and inflammation⁵. Since CETP inhibitors (CETPi) are known 23 24 to increase HDL concentrations, which are the predominant acceptors of cell cholesterol and 25 have been reported to inhibit β -cell apoptosis and promote β -cell survival, it follows that this

therapeutic strategy may be important for maintaining normal β-cell function and insulin secretion⁶. Indeed, previous meta-analyses of existing randomized controlled clinical trials of CETPi therapies have shown that CETP inhibitors significantly reduce the incidence of new onset diabetes while improving glucose homeostasis and metabolism⁷. Therefore, in this study, we speculated that synergistic effects might be jointly induced by a combination of SGLT2i and CETPi therapy. We computationally tested this hypothesis through the design of a new 2x2 factorial Mendelian randomization study comprised of 233,765 individuals from the UK Biobank. Our study builds upon and improves on prior work exploring the efficacy of combination therapies in smaller populations that focused on other clinical indications and drugs (e.g., previous efforts to genetically mimic the effects of ezetimibe and statins in 108,376 people with coronary heart disease⁸).

1 Methods

2 Construction of genetic scores

To construct a genetic score that computationally mimics the biological effects of CETP inhibitors, we build a score of 4 single-nucleotide polymorphisms (SNPs) in the CETP gene region that are strongly correlated with HDL. The genetic score uses all genotyped SNPs in the UK Biobank that were included in a CETP score described in a prior study^{9,10}. A higher CETP genetic score mimics a greater degree of pharmaceutical CETP inhibition (Figure 1A,B). SNPs are filtered for inclusion such that they are all approximately in linkage disequilibrium (LD) with r^2<0.3 (Supplementary Table 4 and 5).

10

To construct a genetic score that mimics the effects of SGLT2 inhibitors, we build a score of 2
single-nucleotide polymorphisms (SNPs) in the SGLT2 gene region that are strongly correlated
with SGLT2 expression. The genetic score uses all genotyped SNPs in the UK Biobank
genotyping information that were included in the SGLT2 score described in Katzmann et al.,
2021^{9,11}. A higher SGLT2 genetic score mimics a greater degree of pharmaceutical SGLT2
inhibition (Figure 1C,D).

17

18 Instrumental variable data analysis

We perform a 2x2 factorial Mendelian Randomization (MR) analysis using the UK Biobank
with a focus on CETP and SGLT2-relevant datasets, as outlined in Figure 2A and Figure 2C.
We include all individuals in the UK Biobank that have genotyping information containing
all SNPs needed to construct the genetic scores, as well as all biomarker values. Furthermore,
only white British individuals are included in the analysis to control for population
stratification bias. This is performed because the SGLT2 score from Katzman et al., 2021 is
validated only in the white population of the UK Biobank since the eQTLs from which they

were constructed were identified in a primarily white population^{11,12}. In total, 233,765
 individuals fulfil our study's inclusion criteria. The final study population is then analyzed
 with the 2x2 factorial MR methodology detailed in Figure 2B.

4

Individuals are separated into two groups based on whether their CETP genetic score is 5 6 greater than or less than the median CETP score. In each group, individuals are then 7 separated into two additional groups based on whether their SGLT2 genetic score is greater 8 than or less than the median SGLT2 genetic score. In total, four groups are formed. Then, 9 the mean age, sex, HDL, LDL, TG, ApoB, weight, systolic blood pressure (SBP), glycated 10 hemoglobin, and diabetes incidence rates are recorded for each of the four groups in both the discovery and replication cohorts. Differences in quantitative variables between groups are 11 12 evaluated using linear regression and differences in diabetes incidence are calculated using 13 logistic regression. We conduct analysis controlling for body mass index (BMI) and systolic 14 blood pressure (SBP) using linear regression for glycated hemoglobin and logistic regression 15 for diabetes, though analysis excluding SBP and BMI as covariates is also conducted. The 16 covariates of BMI and SBP are included in the regression models because the SGLT2 genetic score used to mimic SGLT2 inhibition is associated with increased SBP and BMI, which is 17 18 the opposite direction of effect that pharmaceutical SGLT2 inhibition has on these variables. 19 BMI and SBP are included as covariates to ensure that the difference in glycated hemoglobin 20 observed between groups is not due to these associations. Diabetes incidence is defined by 21 International Classification of Diseases (ICD) codes retrieved from the electronic medical 22 health records database associated with the UK Biobank. All individuals included in this 23 analysis have available health records. Non-additive effects between genetic CETP and 24 SGLT2 scores are detected through linear regressions with CETP, SGLT2, and their product 25 (non-additive term) against glycated hemoglobin and logistic regression against diabetes

incidence. Interaction is detected as a significant p-value in the interaction term of the
regression.
Statistical Analysis
All analysis is performed in the R programming language, v4.1.0 ¹³ . All visualization is
performed using the ggplot2 package in R ¹⁴ . All hypothesis tests are two-sided and use a
statistical significance level of 0.05.
Study/Ethics Approval
All participants gave written informed consent prior to data collection. UK Biobank has full
ethical approval from the NHS National Research Ethics Service (16/NW/0274). All
methods were carried out in accordance with relevant guidelines and regulations. UK
Biobank data is available to researchers upon request (https://www.ukbiobank.ac.uk/enable-
your-research).

1 **Results**

2 Confirming Genetic Score Function

3 Pharmaceutical CETP inhibition is known to increase HDL and decrease LDL along with ApoB^{15,16,17,18,19}. Thus, we validated whether our CETP genetic score behaved similarly to 4 5 pharmaceutical CETP inhibition by seeing if elevated CETP genetic scores, corresponding to 6 more CETP inhibition, exhibited these same relationships. This validation was performed 7 through a dichotomous CETP score, where participants are split into high and low groups and 8 differences in lipid biomarkers are observed, as well as through a continuous CETP score, 9 where the score itself is regressed against HDL, LDL, and ApoB. We find both scores are 10 strongly associated with increased HDL, decreased LDL, and decreased ApoB with p-values 11 less than $2x10^{-16}$ for all comparisons (Figure 1A, 1B; Supplementary Table 1). Based on 12 these results, our CETP score is likely a reasonable proxy for pharmaceutical CETP inhibition. 13

14 Pharmaceutical SGLT2 inhibition decreases glycated hemoglobin, systolic blood pressure, and 15 body mass index (BMI), so we validate the function of our SGLT2 genetic score based on associations with these biomarkers^{20,21,22,23}. We perform the same analysis with dichotomous 16 17 and continuous scores as detailed above to validate our CETP genetic score, finding that our SGLT2 score is associated with decreased glycated hemoglobin (dichotomized: p=4.26x10^-18 19 5; continuous: $p=4.40x10^{-5}$), but increased systolic blood pressure (dichotomized: p=0.0116; 20 continuous: p=0.00149) with increased BMI trending towards significance (dichotomized: 21 p=0.172; continuous: p=0.0708) (Figure 1C, 1D; Supplementary Table 1). Based on these 22 results, we conclude that our SGLT2 score functions as expected with respect to glycated 23 hemoglobin, but not with respect to SBP and BMI. Since the primary mechanism of action of 24 SGLT2 inhibition is to decrease glycated hemoglobin with decreased blood pressure and BMI 25 as secondary effects, we believe our SGLT2 score is likely a reasonable proxy for

pharmaceutical SGLT2 inhibition. However, we will control for the possible confounding of
the SBP and BMI associations by including them as covariates in all aspects of the following
2x2 factorial Mendelian Randomization analysis. For each comparison between groups there
will be two statistical tests performed: one without SBP and BMI as covariates and one
including SBP and BMI as covariates.

6

7 Comparison of glycated hemoglobin between groups

8 After confirming the function of our scores and identifying SBP and BMI as possible 9 confounders to control for, we proceed with our 2x2 factorial Mendelian Randomization 10 analysis and split our cohort into four groups corresponding to control, SGLT2 inhibition only (SGLT2i), CETP inhibition only (CETPi), and both SGLT2 and CETP inhibition (combo 11 12 therapy). We compare the levels of glycated hemoglobin between members of each group and 13 the reference group (low CETP and low SGLT2 score). We find that both SGLT2i (p=0.0719) 14 and CETPi (p=0.0549) are associated with decreased glycated hemoglobin relative to control, 15 and this signal is strengthened to statistical significance (SGLT2i: p=0.0087; CETPi: p=0.044) when SBP and BMI are included as covariates (Figure 3A, 3B; Supplementary Table 2). 16 Furthermore, when the non-control groups are compared against each other, no significant 17 18 difference is found between the CETPi and SGLT2i groups (p=0.915), but the combo therapy 19 group has significantly lower glycated hemoglobin levels relative to the SGLT2i (p=0.00558) 20 and CETPi (p=0.00118) groups; this conclusion is recapitulated when SBP and BMI are 21 included as covariates (CETPi vs SGLT2i: p=0.384; Combo vs SGLT2i: p=0.0459; Combo vs 22 CETPi: p=0.00146) (Figure 3C, 3D; Supplementary Table 2). Non-additive effects between 23 genetic CETP and SGLT2 inhibition on glycated hemoglobin are not detected, as the 24 interaction term is not significantly associated with glycated hemoglobin (Estimate: 9.13x10^-25 5; 95% CI: -0.0007 to 0.0007; p-value=0.98) (Supplement 9).

1 Comparison of diabetes risk between groups

2 To determine whether joint CETP and SGLT2 inhibition has an impact on diabetes risk within 3 each of our groups, we leverage the same analytical framework as detailed above for glycated 4 hemoglobin but use logistic regression instead of linear regression because diabetes is a binary 5 phenotype. We find that neither CETPi nor SGLT2i are associated with decreased diabetes risk 6 relative to control (CETPi: p=0.806; SGLT2i: p=0.274), but combo therapy is associated with 7 significantly decreased diabetes risk relative to control (p=4.44x10^-3) (Figure 4A; 8 Supplementary Table 3). These findings are unchanged if SBP and BMI are included as 9 covariates (CETPi: p=0.446; SGLT2i: p=0.233; Combo: p=3.82x10^-3) (Figure 4B; 10 Supplementary Table 3). Comparison between groups suggests that SGLT2i and CETPi do not have significantly different incidence of diabetes (p=0.444), even though the combo therapy 11 12 group is significantly associated with decreased diabetes incidence relative to SGLT2i 13 (p=0.0149) and is trending towards significance relative to CETPi (p=0.0557) (Figure 4C; 14 Supplementary Table 3). Replication of these findings is achieved when SBP and BMI are 15 included as covariates (CETPi vs SGLT2i: p=0.739; Combo vs SGLT2i: p=0.0466; Combo vs CETPi: p=0.0609) (Figure 4D; Supplementary Table 3). Non-additive effects between genetic 16 17 CETP and SGLT2 inhibition on diabetes risk are not detected, as the interaction term is not 18 significantly associated with diabetes risk (Estimate: -0.00233; 95% CI: -0.008 to 0.004; p-19 value=0.454) (Supplement 9). A summary of all evaluated quantities between different groups 20 in the 2x2 factorial framework is presented in Figure 5.

- 21
- 22
- 23
- 24
- 25

12

1 **Discussion**

2 In this study, we have used a 2x2 factorial Mendelian Randomization framework to investigate 3 the effects of SGLT2i and CETPi combination therapy on glycated hemoglobin levels and 4 diabetes risk. We find that combination therapy is associated with decreased glycated 5 hemoglobin levels compared to SGLT2i, CETPi, and control, with this conclusion robust 6 against the inclusion of potential confounders (SBP and BMI) as covariates. The combination 7 therapy group also had significantly lower diabetes incidence compared to both control and 8 SGLT2i and was trending towards significance for CETPi. We detected no evidence of 9 interactions between genetic CETP and SGLT2 inhibition on either glycated hemoglobin or 10 diabetes risk. Taken together, these results constitute genetics-driven evidence suggesting that 11 combination therapy with CETP and SGLT2 inhibitors confers improved protection against 12 hyperglycemia and diabetes risk compared to SGLT2 inhibitors alone. Furthermore, the lack 13 of interaction effect suggests that genetic CETP or SGLT2 inhibition doesn't attenuate the 14 effect of the other on glycated hemoglobin or diabetes risk. It is important to note that since 15 CETP and SGLT2 inhibitors are both oral drugs, their combination therapy represents an oral 16 therapeutic strategy for treatment-resistant diabetes prior to use of injectable drugs such as 17 insulin or glucagon-like peptide 1 (GLP1) receptor agonists²⁴. The ease of taking oral therapy 18 over injectable drugs could lead to higher patient compliance to drive better patient outcomes 19 as well as lower metabolic disease morbidity. Indeed, previous investigations of medication 20 adherence in type-2 diabetes estimate adherence of oral hyperglycemia agents to be between 21 38% and 93%, generally higher than that of injectable hyperglycemia agents, which are between 38% and 61%^{25,26,27,28,29}. 22

23

The cost of bringing a new drug to market is exceptionally high, costing over \$1 billion with
estimates ranging as high as \$2.6 billion^{30,31}. Beyond heavy monetary investment, developing

1 medicine to treat a disease from scratch requires a time investment of over a decade^{31,32}. 2 Finding ways to repurpose existing drugs into promising new clinical indications represents an 3 efficient way to decrease drug discovery cost and development time. Critically, since CETP 4 inhibitors such as obicetrapib are currently in phase 3 clinical trials to treat dyslipidemia and 5 coronary artery disease, its clean safety and toxicity profile makes it a good repurposing 6 candidate for metabolic disease and combination therapies³³. Our analysis not only provides 7 genetics-driven support for repurposing CETP inhibitors to metabolic disease in the form of a 8 CETP and SGLT2 inhibitor combination therapy, but also highlights the power of 2x2 factorial 9 Mendelian Randomization as a computational framework through which combination 10 therapies across disease verticals can be systematically discovered and mined for repurposing opportunities. Previous 2x2 factorial MR studies have identified combination therapies 11 12 primarily within cardiovascular disease for PCSK9 and CETP inhibition, NPC1L1 and HMGCR inhibition, and IL-6 and PCSK9/CETP/NPC1L1 inhibition^{8,34,35}. However, our study 13 14 is the first to use 2x2 factorial MR as a way to identify phase 3 cardiovascular drugs that can 15 be repurposed for metabolic disease in a combination therapy approach. This conclusion is currently patent-pending under application number 37726-54665. 16

17

18 Despite the translational impact of our findings, our study is not without its limitations. The 19 primary shortcoming of our analysis is the fact that we did not conduct a randomized double-20 blind placebo-controlled clinical trial, which is the gold benchmark standard, to administer 21 pharmacologic SGLT2 or CETP inhibitors to investigate the effect of either monotherapy. 22 Rather, we computationally analysed the effect of lifetime decreased SGLT2 or CETP 23 function caused be genetic variation, which could differ from the shorter-acting effects of 24 pharmaceutical therapies. Since our approach is grounded in genetics, it also doesn't account 25 for the potential off-target effects of small molecule inhibitors of either SGLT2 or CETP,

14

1	which can only be achieved through a randomized control trial as mentioned above.
2	However, our analysis does provide strong genetics-driven evidence grounded in a well-
3	established causal inference framework that can be used to inform future clinical trials of this
4	combination therapy. Furthermore, the actual instruments may have pleiotropic effects on
5	glycated hemoglobin or lipid parameters independent of their effect on SGLT2 or CETP
6	function, though we have attempted to minimize this potential source of confounding by
7	using previously validated genetic scores from the published literature. Lastly, our analysis
8	demonstrates the effectiveness of joint CETP and SGLT2 inhibition in a white population
9	within the UK Biobank, but the strength and generalizability of our analysis would be
10	increased by are more ethnically diverse data cohort, either by including all individuals in the
11	UK Biobank or by using a more heterogeneous cohort such as the NIH All of Us Research
12	Program ³⁶ .
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	

1 Conclusion

- 2 Genetically downregulated SGLT2 signaling and genetically lowered CETP activity are
- 3 associated with additively lower lifetime risk of metabolic outcomes by way of significantly
- 4 decreased glycated hemoglobin levels and lower incidence of type-2 diabetes. Future clinical
- 5 trials should explore the protective effects of combining SGLT2 inhibitors and CETP-
- 6 lowering treatments in the context of metabolic disease prevention.

1 **Contributions**

2	BBK, MD, JJP, MHD designed the research studies. BBK, PS acquired data. BBK, PS
3	analyzed data and helped with data interpretation and figure generation. BBK wrote the original
4	draft of the manuscript. All authors reviewed and edited the manuscript.
5	

6 Acknowledgement

7 BBK acknowledges funding support from Indiana University and NIH R01DK132090.

8

9 Disclosures

10 BBK is the co-founder of Dock Therapeutics, Inc. JJPK and MHD are co-founders of

11 NewAmsterdam Pharma, B.V.

1 **References**

2	1. Hirode G, Wong RJ. Trends in the prevalence of metabolic syndrome in the united states,
3	2011-2016. JAMA. 2020;323(24):2526. doi:10.1001/jama.2020.4501
4	
5	2. Shyr ZA, Yan Z, Ustione A, Egan EM, Remedi MS. SGLT2 inhibitors therapy protects
6	glucotoxicity-induced β -cell failure in a mouse model of human KATP-induced diabetes
7	through mitigation of oxidative and ER stress. Cras-Méneur C, ed. PLoS ONE.
8	2022;17(2):e0258054. doi:10.1371/journal.pone.0258054
9	
10	3. Heerspink HJL, Perkins BA, Fitchett DH, Husain M, Cherney DZI. Sodium glucose
11	cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney
12	effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752-772.
13	doi:10.1161/CIRCULATIONAHA.116.021887
14	
15	4. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the
16	treatment of type 2 diabetes mellitus. <i>Diabetes</i> . 2009;58(4):773-795. doi:10.2337/db09-9028
17	
18	5. Guo W, Gong Y, Fu Z, et al. The effect of cholesteryl ester transfer protein on pancreatic
19	beta cell dysfunction in mice. Nutr Metab (Lond). 2016;13(1):21. doi:10.1186/s12986-016-
20	0082-1
21	
22	6. Fryirs MA, Barter PJ, Appavoo M, et al. Effects of high-density lipoproteins on pancreatic
23	β-cell insulin secretion. ATVB. 2010;30(8):1642-1648. doi:10.1161/ATVBAHA.110.207373
24	

18

1	7. Masson W, Lobo M, Siniawski D, et al. Therapy with cholesteryl ester transfer protein			
2	(Cetp) inhibitors and diabetes risk. Diabetes & Metabolism. 2018;44(6):508-513.			
3	doi:10.1016/j.diabet.2018.02.005			
4				
5	8. Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD. Effect of naturally random			
6	allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease			
7	mediated by polymorphisms in npc111, hmgcr, or both. Journal of the American College of			
8	Cardiology. 2015;65(15):1552-1561. doi:10.1016/j.jacc.2015.02.020			
9				
10	9. Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping			
11	and genomic data. Nature. 2018;562(7726):203-209. doi:10.1038/s41586-018-0579-z			
12				
13	10. Ference BA, Kastelein JJP, Ginsberg HN, et al. Association of genetic variants related to			
14	cetp inhibitors and statins with lipoprotein levels and cardiovascular risk. JAMA.			
15	2017;318(10):947-956. doi:10.1001/jama.2017.11467			
16				
17	11. Katzmann JL, Mason AM, März W, et al. Genetic variation in sodium-glucose			
18	cotransporter 2 and heart failure. Clin Pharmacol Ther. 2021;110(1):149-158.			
19	doi:10.1002/cpt.2153			
20				
21	12. Lonsdale J, Thomas J, Salvatore M, et al. The genotype-tissue expression (Gtex) project.			
22	Nat Genet. 2013;45(6):580-585. doi:10.1038/ng.2653			
23				
24	13. R: the r project for statistical computing. Accessed April 30, 2023. https://www.r-			
25	project.org/			

1	14. Wickham H. Ggplot2: Elegant Graphics for Data Analysis. 2nd ed. 2016. Springer
2	International Publishing : Imprint: Springer; 2016.
3	
4	15. Tall AR, Rader DJ. Trials and tribulations of cetp inhibitors. Circ Res. 2018;122(1):106-
5	112. doi:10.1161/CIRCRESAHA.117.311978
6	
7	16. Holmes MV, Smith GD. Revealing the effect of CETP inhibition in cardiovascular
8	disease. Nat Rev Cardiol. 2017;14(11):635-636. doi:10.1038/nrcardio.2017.156
9	
10	17. Nicholls SJ, Ditmarsch M, Kastelein JJ, et al. Lipid lowering effects of the CETP
11	inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial.
12	Nat Med. 2022;28(8):1672-1678. doi:10.1038/s41591-022-01936-7
13	
14	18. Nicholls SJ, Brewer HB, Kastelein JJP, et al. Effects of the cetp inhibitor evacetrapib
15	administered as monotherapy or in combination with statins on hdl and ldl cholesterol: a
16	randomized controlled trial. JAMA. 2011;306(19):2099-2109. doi:10.1001/jama.2011.1649
17	
18	19. Nicholls SJ. Cetp-inhibition and hdl-cholesterol: a story of cv risk or cv benefit, or both.
19	Clin Pharmacol Ther. 2018;104(2):297-300. doi:10.1002/cpt.1118
20	
21	20. Kawasoe S, Maruguchi Y, Kajiya S, et al. Mechanism of the blood pressure-lowering
22	effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes.
23	BMC Pharmacol Toxicol. 2017;18(1):23. doi:10.1186/s40360-017-0125-x
24	
25	21. Cho YK, Kim YJ, Jung CH. Effect of sodium-glucose cotransporter 2 inhibitors on

1	weight reduction in overweight and obese populations without diabetes: a systematic review			
2	and a meta-analysis. Journal of Obesity & Metabolic Syndrome. 2021;30(4):336-344.			
3	doi:10.7570/jomes21061			
4				
5	22. Teo YH, Teo YN, Syn NL, et al. Effects of sodium/glucose cotransporter 2 (Sglt2)			
6	inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: a			
7	systematic review and meta-analysis of randomized-controlled trials. JAHA.			
8	2021;10(5):e019463. doi:10.1161/JAHA.120.019463			
9				
10	23. Adamson C, Kondo T, Jhund PS, et al. Dapagliflozin for heart failure according to body			
11	mass index: the DELIVER trial. European Heart Journal. 2022;43(41):4406-4417.			
12	doi:10.1093/eurheartj/ehac481			
13				
14	24. Armitage J, Holmes MV, Preiss D. Cholesteryl ester transfer protein inhibition for			
15	preventing cardiovascular events. Journal of the American College of Cardiology.			
16	2019;73(4):477-487. doi:10.1016/j.jacc.2018.10.072			
17				
18	25. Alatorre C, Fernández Landó L, Yu M, et al. Treatment patterns in patients with type 2			
19	diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence			
20	and persistence with dulaglutide compared with once-weekly exenatide and liraglutide:			
21	ALATORRE ET AL . Diabetes Obes Metab. 2017;19(7):953-961. doi:10.1111/dom.12902			
22				
23	26. Krass I, Schieback P, Dhippayom T. Adherence to diabetes medication: a systematic			
24	review. Diabet Med. 2015;32(6):725-737. doi:10.1111/dme.12651			

1	27. Mody R, Huang Q, Yu M, et al. Adherence, persistence, glycaemic control and costs
2	among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or
3	exenatide once weekly at 12-month follow-up in a real-world setting in the United States.
4	Diabetes Obes Metab. 2019;21(4):920-929. doi:10.1111/dom.13603
5	
6	28. Mody R, Manjelievskaia J, Marchlewicz EH, et al. Greater adherence and persistence
7	with injectable dulaglutide compared with injectable semaglutide at 1-year follow-up: data
8	from us clinical practice. Clinical Therapeutics. 2022;44(4):537-554.
9	doi:10.1016/j.clinthera.2022.01.017
10	
11	29. Yu M, Xie J, Fernandez Lando L, Kabul S, Swindle RW. Liraglutide versus exenatide
12	once weekly: persistence, adherence, and early discontinuation. Clinical Therapeutics.
13	2016;38(1):149-160. doi:10.1016/j.clinthera.2015.11.017
14	
15	30. Wouters OJ, McKee M, Luyten J. Estimated research and development investment
16	needed to bring a new medicine to market, 2009-2018. JAMA. 2020;323(9):844.
17	doi:10.1001/jama.2020.1166
18	
19	31. Mohs RC, Greig NH. Drug discovery and development: Role of basic biological research.
20	Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2017;3(4):651-
21	657. doi:10.1016/j.trci.2017.10.005
22	
23	32. Tamimi NAM, Ellis P. Drug development: from concept to marketing! Nephron Clin
24	Pract. 2009;113(3):c125-c131. doi:10.1159/000232592
25	

1	33. New Amsterdam Pharma. A Placebo-Controlled, Double-Blind, Randomized Phase 3
2	Study to Evaluate the Effect of 10mg Obicetrapib in Participants with HeFH and/or ASCVD
3	Who Are Not Adequately Controlled by Their Lipid Modifying Therapies. Clinicaltrials.gov;
4	2023. Accessed May 23, 2023. https://clinicaltrials.gov/ct2/show/NCT05142722
5	
6	34. Cupido AJ, Reeskamp LF, Hingorani AD, et al. Joint genetic inhibition of pcsk9 and cetp
7	and the association with coronary artery disease: a factorial mendelian randomization study.
8	JAMA Cardiol. 2022;7(9):955. doi:10.1001/jamacardio.2022.2333
9	
10	35. Georgakis MK, Malik R, Burgess S, Dichgans M. Additive effects of genetic interleukin-
11	6 signaling downregulation and low-density lipoprotein cholesterol lowering on
12	cardiovascular disease: a 2×2 factorial mendelian randomization analysis. JAHA.
13	2022;11(1):e023277. doi:10.1161/JAHA.121.023277
14	
15	36. The All of Us Research Program Investigators. The "all of us" research program. N Engl
16	J Med. 2019;381(7):668-676. doi:10.1056/NEJMsr1809937
17	
18	
19	
20	
21	
22	
23	
24	
25	

1 Figures





3 Figure 1: Construction of Genetic Scores

4 Both dichotomous A) and continuous B) CETP scores are associated with decreased ApoB,

5 increased HDL, and decreased LDL. Point estimates and 95% confidence intervals are

6 plotted for the difference between the high-CETP score group. Both dichotomous C) and

7 continuous **D**) SGLT2 scores are associated with decreased hemoglobin A1c and increased

8 systolic blood pressure, with increased BMI trending towards significance.



1 Figure 2: Graphical abstract of methods overview.

2 A) Overview of computational workflow for the 2x2 factorial Mendelian Randomization (MR) split into 3 steps: identifying SNPs for the genetic scores that mimic effects of CETP and 3 4 SGLT2 inhibition, calculating the genetic scores, calculating biomarker averages and disease 5 incidence for each of the four groups. B) Description of allocating individuals into one of the four groups: Low CETP and low SGLT2 score, low CETP and high SGLT2 score, high CETP 6 7 and low SGLT2 score, and high CETP and high SGLT2 score. The same 2x2 factorial MR 8 methods were conducted with each group. C) Once genetic scores were obtained and 9 individuals separated into one of the four aforementioned groups, a 2x2 factorial MR analysis 10 was performed using UK Biobank with a focus on CETP and SGLT2-relevant datasets comprising 233,765 unique individuals. 11



Figure 3: All groups in the 2x2 factorial Mendelian Randomization framework are compared
against control to see if they have lower glycated hemoglobin levels. This is performed A)
without SBP and BMI as covariates and B) with SBP and BMI as covariates. Non-control
groups are then compared with each other C) without SBP and BMI as covariates and D) with
SBP and BMI as covariates.

7



Figure 4: All groups in the 2x2 factorial Mendelian Randomization framework are compared
against control to see if they have lower diabetes incidence. This is performed A) without
SBP and BMI as covariates and B) with SBP and BMI as covariates. Non-control groups are
then compared with each other C) without SBP and BMI as covariates and D) with SBP and
BMI as covariates.

	Reference	SGLT2i	СЕТРІ	Combo
Demographics	57444	45 404	72.000	50.474
No. of Participants	5/114	45 491	72 986	58 1/4
Age	56.84 (8.02)	56.91 (7.98)	56.86 (7.99)	56.82 (8.02)
Number Male (%)	26 316 (46.1)	20 866 (45.9)	33 597 (46.0)	26 757 (46.0)
Number Female (%)	30 798 (53.9)	24 625 (54.1)	39 389 (54.0)	31 417 (54.0)
Smoking				
Never (%)	30 628 (53.6)	24 680 (54.3)	39 797 (54.5)	31 481 (54.1)
Previous (%)	20 461 (35.8)	16 006 (35.2)	25 556 (35.0)	20 450 (35.2)
Current (%)	20 461 (10.2)	4 632 (10.2)	7 401 (10.1)	6 033 (10.4)
Prefer not to answer (%)	196 (0.34)	173 (.38)	232 (0.32)	210 (0.36)
Alcohol				
Daily or almost daily (%)	12 185 (21.3)	9 732 (21.4)	15 477 (21.2)	12 615 (21.7)
Three of four times a week (%)	13 744 (24.1)	10 953 (24.1)	17 618 (24.1)	13 867 (23.8)
Once or twice a week (%)	15 069 (26.4)	12 036 (26.5)	19 260 (26.4)	15 279 (26.3)
One to three times a month (%)	6 385 (11.2)	5 008 (11.0)	8 027 (11.0)	6 506 (11.2)
Special occasions only (%)	5 960 (10.4)	4 809 (10.6)	7 738 (10.6)	6 065 (10.4)
Never (%)	3 736 (6.5)	2 926 (6.4)	4 808 (6.6)	3 811 (6.6)
Prefer not to answer (%)	35 (0.06)	27 (0.06)	58 (0.08)	31 (0.05)
Medication Use				
Lipid lowering therapy (%)	10 933 (19.1)	8 801 (19.3)	13 264 (18.2)	10 676 (18.4)
Blood pressure lowering therapy (%)	12 574 (22.0)	10 058 (22.1)	15 810 (21.7)	12 498 (21.5)
Insulin therapy (%)	378 (0.66)	307 (0.68)	450 (0.62)	340 (0.58)
Lipids				
HDL	1.39 (0.36)	1.40 (0.36)	1.50 (0.39)	1.50 (0.39)
LDL	3.60 (0.86)	3.60 (0.86)	3.57 (0.85)	3.56 (0.85)
TG	1.76 (0.99)	1.76 (1.00)	1.72 (0.97)	1.72 (0.97)
АроВ	1.04 (0.24)	1.04 (0.24)	1.03 (0.24)	1.03 (0.24)
Non-lipid biomarkers				
Glycated hemoglobin	35.58 (4.77)	35.52 (4.76)	35.53 (4.72)	35.44 (4.68)
Body mass index	27.36 (4.70)	27.42 (4.70)	27.36 (4.70)	27.33 (4.70)
Systolic blood pressure	140.00 (19.59)	140.37 (19.72)	139.97 (19.61)	140.10 (19.62)
Genetic scores				
CETP score	13.93 (3.50)	13.90 (3.53)	22.41 (2.92)	22.44 (2.92)
SGLT2 score	0.56 (0.27)	1.47 (0.15)	0.56 (0.27)	1.47 (0.15)
Diabetes cases (%)	3806 (6.67)	3014 (6.63)	4753 (6.51)	3637 (6.25)

2 Figure 5: Regression of genetic scores against biomarkers.

1

3 Demographic, biomarker, genetic score, and diabetes data differences between the different

4 groups included in the 2x2 factorial Mendelian randomization design.